explore -WSS

explore

author：comprehensive 2025-09-27 12:56:03 - browse：42416

insulin biosimilar — Last week, the FDA released a trio of guidelines clarifying the way they plan to evaluate devices that go through the 510(k) pathway. Jacquelyn Martin/AP

Five years after promising to fix a flawed regulatory pathway widely used by medical device manufacturers, the Food and Drug Administration has issued new guidelines to improve its so-called 510(k) program that has long been lambasted for letting risky devices fall through the cracks.

Most medical device companies do not have to test their products on people in order to secure clearance from the FDA — they simply have to show they’re “substantially equivalent” to devices already on the market, called “predicates.” This process is the 510(k) pathway, and accounts for the vast majority of new medical devices launched on the market each year. Devices cleared through this pathway include X-ray machines, muscle stimulators, and wheelchairs.

Last week, the FDA released a trio of guidelines clarifying the way it plans to evaluate devices that go through the 510(k) pathway. The agency is asking manufacturers to avoid predicate devices that were recalled due to a “design-related” issue or have “unmitigated” safety concerns. Manufacturers should submit flow charts explaining why they chose their predicate device. If they have to choose one with a recall history or safety issues, they should explain how the new device addresses those problems. The FDA may also ask the manufacturer for clinical data in this case.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： 2023 STAT Wunderkinds: get to know the winners

explore

focus

WSS

New weight loss drugs vying to be the next Wegovy or Mounjaro

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

IRA could hurt research into orphan drugs for rare diseases

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Telehealth for opioid use disorder is lifesaving

First Opinion Podcast: Long Covid needs a new approach

knowledge

explore

explore

Continuity nursing helped my family in our darkest PICU moments

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

How one medical school became remarkably diverse

Pharmacists can make shortage drugs, but at what cost?

How to save PrEP access — and even expand it

FDA panel endorses Alnylam’s heart drug — after picking it apart

How one medical school became remarkably diverse

Long Covid needs a new name — and a new frame

What does generative AI mean for health care? We asked experts

UnitedHealth’s board chair also owns a personal investment firm

entertainment

NIH confirmation hearing shows politicization of research

What to make of Biden’s latest efforts on cancer research

Studies point to risks of excluding people with obesity from drug trials

FDA panel endorses Alnylam’s heart drug — after picking it apart

Walmart eyes Medicare Advantage provider ChenMed

Pharmacists can make shortage drugs, but at what cost?

explore

explore

focus

knowledge